The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Open accessAbstract
PURPOSE: TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is preferentially activated in hypoxic conditions. This phase II study investigated TH-302 in combination with doxorubicin, followed by single-agent TH-302 maintenance therapy in patients with first-line advanced soft tissue sarcoma (STS) to assess progression-free survival (PFS), response rate, overall survival, safety, and tolerability. PATIENTS AND METHODS: In this open-label phase II study, TH-302 300 mg/m(2) was administered intravenously on days 1 and 8 with doxorubicin 75 mg/m(2) on day 1 of each 21-day cycle. After six cycles, patients with stable and/or responding disease could receive maintenance monotherapy with TH-302. RESULTS: Ninety-one patients initiated TH-302 plus doxorubicin induction treatment. The PFS rate at 6 months (primary efficacy measure) was 58% (95% CI, 46% to 68%). Median PFS was 6.5 months (95% CI, 5.8 to 7.7 months); median overall survival was 21.5 months (95% CI, 16.0 to 26.2 months). Best tumor responses were complete response (n = 2 [2%]) and partial response (n = 30 [34%]). During TH-302 maintenance (n = 48), five patients improved from stable disease to partial response, and one patient improved from partial to complete response. The most common adverse events during induction were fatigue, nausea, and skin and/or mucosal toxicities as well as anemia, thrombocytopenia, and neutropenia. These were less severe and less frequent during maintenance. There was no evidence of TH-302-related hepatic, renal, or cardiac toxicity. CONCLUSION: PFS, overall survival, and tumor response compared favorably with historical outcomes achieved with other first-line chemotherapies for advanced STS. A phase III study of TH-302 is ongoing (NCT01440088).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Results from recently published phase II clinical trials for TH-302 in combination with gemcitabine in pancreatic cancer (Borad et al., 2015) or in combination with doxorubicin in soft tissue sarcoma (Chawla et al., 2014) are encouraging, and phase III studies have been initiated.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Chawla et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Judson, I. R., Verweij, J., Gelderblom, H. A. J., Hartmann, J. T., Schöffski, P., Blay, J., Kerst, J. M., Šufliarský, J., Whelan, J. S., Hohenberger, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70063-4 · Cited by 1,185
Detection and Characterization of Tumor Hypoxia Using pO 2 Histography
Vaupel, P., Höckel, M., & Mayer, A. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1628 · Cited by 728
Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R., Verweij, J., Santoro, A., Buesa, J., & Tursz, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.150 · Cited by 608
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981) · PubMed · Cited by 555
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Glabbeke, M. M. V., Verweij, J., Judson, I. R., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 462
Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
Kaanders, J. H. A. M., Wijffels, K. I. E. M., Marres, H. A. M., Ljungkvist, A. S. E., Pop, L. A. M., van den Hoogen, F. J. A., de Wilde, P. C. M., Bussink, J., Raleigh, J. A., & van der Kogel, A. J. (2002) · PubMed · Cited by 357
Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Casali, P. G., & Blay, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq209 · Cited by 260
Lorigan, P. C., Verweij, J., Pápai, Z., Rodenhuis, S., Cesne, A. L., Leahy, M. G., Radford, J. A., Glabbeke, M. M. V., Kirkpatrick, A., Hogendoorn, P. C. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7717 · Cited by 256
Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma
Karavasilis, V., Seddon, B. M., Ashley, S., Al‐Muderis, O., Fisher, C., & Judson, I. R. (2008) · Cancer · doi:10.1002/cncr.23332 · Cited by 253
Rajendran, J. G., Wilson, D. C., Conrad, E. U., Peterson, L. M., Bruckner, J. D., Rasey, J. S., Chin, L. K., Hofstrand, P. D., Grierson, J. R., Eary, J. F., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1096-7 · Cited by 251
Sleijfer, S., Ouali, M., Glabbeke, M. M. V., Krarup‐Hansen, A., Rodenhuis, S., Cesne, A. L., Hogendoorn, P. C. W., Verweij, J., & Blay, J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.09.022 · Cited by 243
Nordsmark, M., Alsner, J., Keller, J. O., Nielsen, O. S., Jensen, O. M., Horsman, M. R., & Overgaard, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1728 · Cited by 228
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Meng, F., Evans, J., Bhupathi, D., Banica, M., Lan, L., Lorente, G., Duan, J.-X., Cai, X., Mowday, A. M., Guise, C. P., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0634 · Cited by 205
Francis, P., Namløs, H. M., Müller, C., Edén, P., Fernebro, J., Berner, J., Bjerkehagen, B., Åkerman, M., Bendahl, P., Isinger-Ekstrand, A., et al. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-73 · Cited by 169
Weiss, G. J., Infante, J. R., Chiorean, E. G., Borad, M. J., Bendell, J. C., Molina, J. R., Tibes, R., Ramanathan, R. K., Lewandowski, K., Jones, S. F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3425 · Cited by 159
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites
Kerbusch, T., de Kraker, J., Keizer, H. J., van Putten, J. W. G., Groen, H. J. M., Jansen, R. L. H., Schellens, J. H. M., & Beijnen, J. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140010-00004 · Cited by 131
Targeting hypoxic tumour cells to overcome metastasis
Bennewith, K. L., & Dedhar, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-504 · Cited by 109
Pretreatment oxygenation profiles of human soft tissue sarcomas
Brizel, D. M., Rosner, G. L., Harrelson, J. M., Prosnitz, L. R., & Dewhirst, M. W. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90950-m · Cited by 104
Whelan, J. S., Casali, P. G., & Blay, J. (2010) · UCL Discovery (University College London) · Cited by 96
Tannock, I. F. (1982) · PubMed · Cited by 88
Ganjoo, K. N., Cranmer, L. D., Butrynski, J. E., Rushing, D. A., Adkins, D., Okuno, S. H., Lorente, G., Kroll, S., Langmuir, V. K., & Chawla, S. P. (2011) · Oncology · doi:10.1159/000327739 · Cited by 81
Self-citationHistology-driven chemotherapy of soft-tissue sarcoma
Eriksson, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq285 · Cited by 55
Systemic therapy for advanced soft tissue sarcomas
Riedel, R. F. (2011) · Cancer · doi:10.1002/cncr.26415 · Cited by 42
Metastatic Soft Tissue Sarcoma in Adults
Nielsen, O. S., Blay, J., Judson, I. R., Glabbeke, M. M. V., Verweij, J., & van Oosterom, A. T. (2003) · American Journal of Cancer · doi:10.2165/00024669-200302030-00005 · Cited by 21
Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1.
Batchelder, R. M., Wilson, W. R., Hay, M. P., & Denny, W. A. (1996) · Europe PMC (PubMed Central) · Cited by 16
Research works printed but not linked: 6
- American Cancer Society, 2008, Cancer Facts & Figures 2008
- Kaanders JH, 2002, Cancer Res, 62, 7066
- Ryan CW, Presented at the European Cancer Congress
- Batchelder RM, 1996, Br J Cancer, 27, S52
- Teicher BA, 1981, Cancer Res, 41, 73
- Tannock I, 1982, Cancer Res, 42, 4921
Cited by
Sorted by citations
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“Results from recently published phase II clinical trials for TH-302 in combination with gemcitabine in pancreatic cancer (Borad et al., 2015) or in combination with doxorubicin in soft tissue sarcoma (Chawla et al., 2014) are encouraging, and phase III studies have been initiated.”
BackgroundHypoxia-targeted drug delivery
Sharma, A. K., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 556
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 541
Metadata
- Authors
- Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic,...
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2014-10-10
- Volume
- 32
- Issue
- 29
- Pages
- 3299-3306
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC4588714
- OpenAlex
- W2162527266
- Cited by
- 155
- References
- 29
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 11 · 2021: 20 · 2020: 10 · 2019: 12 · 2018: 14 · 2017: 17 · 2016: 33 · 2015: 19
- FWCI
- 18.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- GlaxoSmithKline
- Merck KGaA
- EMD Serono
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- TH-302, doxorubicin, soft tissue sarcoma, hypoxia-activated prodrug, combination chemotherapy, maintenance monotherapy, progression-free survival, anticancer activity, drug safety and tolerability, first-line therapy
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Doxorubicin, Female, Humans, Male, Middle Aged, Nitroimidazoles, Phosphoramide Mustards, Prodrugs, Sarcoma, Survival Rate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
